Click Here for 5% Off Your First Aladdin Purchase!

Trilaciclib (G1T28) - 98%, high purity , Cyclin-dependent kinase 6 inhibitor, CAS No.1374743-00-6, Cyclin-dependent kinase 6 inhibitor

  • Moligand™
  • ≥98%
Item Number
T413997
Grouped product items
SKUSizeAvailabilityPrice Qty
T413997-1mg
1mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$49.90
T413997-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$195.90
T413997-10mg
10mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$279.90
T413997-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$599.90

CDK Inhibitors

Basic Description

SynonymsBCP25013 | 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one | trilaciclibum | UNII-U6072DO9XG | 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-t
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsTrilaciclib (G1T28, G1T28-1) is a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Trilaciclib inhibits CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 of 1 nM and 4 nM, respectively.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionCyclin-dependent kinase 6 inhibitor
Product Description

Information

Trilaciclib (G1T28) Trilaciclib (G1T28, G1T28-1) is a highly potent, selective and reversible cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Trilaciclib inhibits CDK4/cyclin D1 and CDK6/cyclin D3 with IC50 of 1 nM and 4 nM, respectively.


Targets

CDK4/cyclin D1 (Cell-free assay); CDK6/cyclin D3 (Cell-free assay) 1 nM; 4 nM


In vitro

G1T28 is a potent and selective CDK4/6 inhibitor that inhibits the phosphorylation of RB and induces an exclusive, reversible G1 arrest. In vitro and in vivo, G1T28 protects RB competent cells from damage by chemotherapy as assessed by gamma-H2A.X (γH2AX) and apoptosis through caspase 3/7 activation.


In vivo

G1T28 regulates the proliferation of HSPCs in both mouse and canine bone marrow, in a reversible, doseand time-dependent manner. Pretreatment of mice with G1T28 allows a faster recovery of complete blood counts (CBCs) following chemotherapy. In addition, G1T28 does not protect RB deficient tumors from chemotherapy but, instead, adds to the anti-tumor effect.


Cell Research(from reference)

Cell lines:HS68 cells, WM2664 cells, A2058 cells 

Concentrations:10 nM, 30 nM, 100 nM, 300 nM, 1000 nM 

Incubation Time:4 h, 8 h, 16 h, 24 h 

Product Properties

ALogP2.6

Associated Targets

CDK7 Tchem Cyclin-dependent kinase 7 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CCNE1 Tchem G1/S-specific cyclin-E1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK9 Tchem Cyclin-dependent kinase 9 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BRD4 Tchem Bromodomain-containing protein 4 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK4 Tclin Cyclin-dependent kinase 4 2 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK2 Tchem Cyclin-dependent kinase 2 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

FGFR3 Tclin Fibroblast growth factor receptor 3 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CSNK1D Tchem Casein kinase I isoform delta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

TRIM24 Tchem Transcription intermediary factor 1-alpha 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

BRPF1 Tchem Peregrin 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

AURKA Tchem Aurora kinase A 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

CDK6 Tclin Cyclin-dependent kinase 6 1 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

ABL1 Tclin Tyrosine-protein kinase ABL1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

GSK3B Tclin Glycogen synthase kinase-3 beta 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

MAPK1 Tchem Mitogen-activated protein kinase 1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name 4-[[5-(4-methylpiperazin-1-yl)pyridin-2-yl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1'-cyclohexane]-10-one
INCHI InChI=1S/C24H30N8O/c1-30-9-11-31(12-10-30)18-5-6-20(25-15-18)28-23-26-14-17-13-19-22(33)27-16-24(7-3-2-4-8-24)32(19)21(17)29-23/h5-6,13-15H,2-4,7-12,16H2,1H3,(H,27,33)(H,25,26,28,29)
InChi Key PDGKHKMBHVFCMG-UHFFFAOYSA-N
Canonical SMILES CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
Isomeric SMILES CN1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
PubChem CID 68029831
Molecular Weight 446.55

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

8 results found

Lot NumberCertificate TypeDateItem
D2403595Certificate of AnalysisJan 25, 2024 T413997
D2403596Certificate of AnalysisJan 25, 2024 T413997
D2403597Certificate of AnalysisJan 25, 2024 T413997
D2403598Certificate of AnalysisJan 25, 2024 T413997
D2403599Certificate of AnalysisJan 25, 2024 T413997
D2403600Certificate of AnalysisJan 25, 2024 T413997
D2403604Certificate of AnalysisJan 25, 2024 T413997
D2403605Certificate of AnalysisJan 25, 2024 T413997

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: Insoluble; Water: Insoluble; Ethanol: Insoluble;

Related Documents

References

1. He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG, Makhuli KM, Wargin WA, Tadema H, van Hoogdalem EJ et al..  (2017)  Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion..  Sci Transl Med,  (387): (589-97).  [PMID:28446688]
2. Bisi JE, Sorrentino JA, Roberts PJ, Tavares FX, Strum JC.  (2016)  Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression..  Mol Cancer Ther,  15  (5): (783-93).  [PMID:26826116]

Solution Calculators